References
Lee JL, Kim MK, Lee KH, Hyun MS, Chung HS, Kim DS, Shin SO, Cho HS, Bae SH, Ryoo HM (2005) Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol 84:13–18
Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456–473
Nuckel H, Meller D, Steuhl KP, Duhrsen U (2004) Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. Eur J Haematol 73:258–262
Morgensztern D, Rosado MF, Serafini AN, Lossos IS (2004) Somatostatin receptor scintigraphy in MALT lymphoma of the lacrimal gland treated with rituximab. Leuk Lymphoma 45:1275–1278
Asproudis I, Gorezis S, Charonis GC, Tolis C, Tsanou E, Agnantis NJ (2005) Mucosa-associated lymphoid tissue lymphoma of the lacrimal gland—a case report. In Vivo 19:1105–1109
Rosado MF, Byrne GE Jr, Ding F, Fields KA, Ruiz P, Dubovy SR, Walker GR, Markoe A, Lossos IS (2006) Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood 107:467–472
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Benetatos, L., Alymara, V., Asproudis, I. et al. Rituximab as first line treatment for MALT lymphoma of extraocular muscles. Ann Hematol 85, 625–626 (2006). https://doi.org/10.1007/s00277-006-0134-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-006-0134-0